Business Description
Chimeric Therapeutics Ltd
ISIN : AU0000121576
Share Class Description:
ASX:CHM: Ordinary SharesDescription
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.85 | |||||
| Equity-to-Asset | 0.16 | |||||
| Debt-to-Equity | 1.46 | |||||
| Debt-to-EBITDA | -0.3 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 40.5 | |||||
| 3-Year EPS without NRI Growth Rate | 38.4 | |||||
| 3-Year FCF Growth Rate | 47.3 | |||||
| 3-Year Book Growth Rate | -65.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 14.12 | |||||
| 9-Day RSI | 28 | |||||
| 14-Day RSI | 31.75 | |||||
| 6-1 Month Momentum % | -57.14 | |||||
| 12-1 Month Momentum % | -70 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.32 | |||||
| Quick Ratio | 0.32 | |||||
| Cash Ratio | 0.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -36.7 | |||||
| Shareholder Yield % | -117.73 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -170.91 | |||||
| ROA % | -58.43 | |||||
| ROIC % | -128.01 | |||||
| ROC (Joel Greenblatt) % | -8198.21 | |||||
| ROCE % | -124.56 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3 | |||||
| EV-to-EBIT | -0.78 | |||||
| EV-to-Forward-EBIT | -0.86 | |||||
| EV-to-EBITDA | -0.78 | |||||
| EV-to-Forward-EBITDA | -0.71 | |||||
| EV-to-FCF | -1.26 | |||||
| Earnings Yield (Greenblatt) % | -128.21 | |||||
| FCF Yield % | -84.17 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Chimeric Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | -0.018 | ||
| Beta | 2 | ||
| Volatility % | 67.9 | ||
| 14-Day RSI | 31.75 | ||
| 14-Day ATR (A$) | 0.001113 | ||
| 20-Day SMA (A$) | 0.009825 | ||
| 12-1 Month Momentum % | -70 | ||
| 52-Week Range (A$) | 0.009 - 0.043 | ||
| Shares Outstanding (Mil) | 995.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Chimeric Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Chimeric Therapeutics Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Chimeric Therapeutics Ltd Frequently Asked Questions
What is Chimeric Therapeutics Ltd(ASX:CHM)'s stock price today?
The current price of ASX:CHM is A$0.01. The 52 week high of ASX:CHM is A$0.04 and 52 week low is A$0.01.
When is next earnings date of Chimeric Therapeutics Ltd(ASX:CHM)?
The next earnings date of Chimeric Therapeutics Ltd(ASX:CHM) is .
Does Chimeric Therapeutics Ltd(ASX:CHM) pay dividends? If so, how much?
Chimeric Therapeutics Ltd(ASX:CHM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers